secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2024-06-12T23:59:59+00:00
Accession:  0001104659-24-070914
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics discontinues NP program after oral difelikefalin fails Part A of KOURAGE-1 study
--------------------------------------------------------------------------------

- Oral difelikefalin did not demonstrate meaningful clinical benefit at any dose vs. placebo in Part A of KOURAGE-1 study for notalgia paresthetica.
- Company discontinues clinical program in NP and will explore strategic alternatives to maximize shareholder value.
- Cash, cash equivalents, and marketable securities were approximately $70 million as of March 31, 2024.
- Drug was well tolerated; safety profile similar to prior trials. Part A enrolled 214 patients across four arms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924070914/0001104659-24-070914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924070914/tm2416682d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-070914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer